Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE
Shareholders who purchased shares of RARE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: August 3, 2023 to
DEADLINE:
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Ultragenyx gave created falsely optimistic beliefs for its investors regarding the performance of its drug candidate in its Phase III trial. The Company failed to achieve statistically significant endpoints despite its optimistic communications. Based on these facts, Ultragenyx's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate .
WHY DJS LAW GROUP?
Join the case to recover your losses.
This press release may be considered
CONTACT:
Phone: 914-206-9742
Email: David@djslawllp.com
View original content:https://www.prnewswire.com/news-releases/ultragenyx-pharmaceutical-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--rare-302694326.html
SOURCE